Information  X 
Enter a valid email address

Horizon Dis Grp plc (HZD)

  Print      Mail a friend

Friday 15 March, 2019

Horizon Dis Grp plc

Director/PDMR Shareholding

RNS Number : 0885T
Horizon Discovery Group plc
15 March 2019

Horizon Discovery Group plc

15 March 2019



Horizon Discovery Group plc

Director/PDMR Shareholding

Cambridge, UK, 15 March 2019: Horizon Discovery Group plc (LSE: HZD) ("Horizon", "the Group" or "the Company"), a global leader in gene editing and gene modulation technologies, announces that 70,730 options were granted today over the Company's ordinary shares of 1 pence each ("Ordinary Shares") to Terry Pizzie, CEO, in accordance with the Company's Long Term Incentive Plan.  The options have an exercise price of 1 pence per share and will vest equally on each of the second and third anniversaries of the grant date. 

The options granted are equivalent to 0.047% of the Company's existing issued share capital. 


For further information from Horizon Discovery Group plc, please contact:

Horizon Discovery Group plc

Terry Pizzie, Chief Executive Officer

Jayesh Pankhania, Chief Financial Officer

Tel: +44 (0) 1223 655 580

Numis Securities Limited (Broker and NOMAD)

Michael Meade / Freddie Barnfield / Duncan Monteith

Tel: +44 (0) 207 260 1000

Consilium Strategic Communications (Financial Media and Investor Relations)

Mary-Jane Elliott / Matthew Neal / Melissa Gardiner

Tel: +44 (0) 20 3709 5700

Email: [email protected]

About Horizon Discovery Group plc

Horizon Discovery Group plc (LSE: HZD) ("Horizon") is a world leader in gene editing and gene modulation technologies. Horizon designs and engineers cells using its translational genomics platform, a highly precise and flexible suite of DNA editing tools (rAAV, ZFN, CRISPR and Transposon) and, following the acquisition of Dharmacon, Inc., its functional genomics platform comprising gene knockdown (RNAi) and gene expression (cDNA, ORF) tools, for research and clinical applications that advance human health. Horizon's platforms and capabilities enable researchers to alter almost any gene or modulate its function in human or mammalian cell-lines.

Horizon offers an extensive range of catalogue products and related research services to support a greater understanding of the function of genes across all species and the genetic drivers of human disease and the development of personalised molecular, cell and gene therapies. These have been adopted by over 10,000 academic, drug discovery, drug manufacturing and clinical diagnostics customers around the globe, as well as in the Company's own R&D pipeline.

Horizon is headquartered in Cambridge, UK, and is listed on the London Stock Exchange's AIM market under the ticker "HZD".



Details of the person discharging managerial responsibilities/person closely associated



Terry Pizzie


Reason for the notification



Chief Executive Officer - PDMR


Initial notification /Amendment

Initial Notification


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor



Horizon Discovery Group plc


Legal Entity Identifier



Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted


Description of the financial instrument, type of instrument

 Identification code

Options over ordinary shares of 1.0 pence each



Nature of the transaction

Grant of Options





Price(s) and volume(s)

Exercise Price

No. of shares





Aggregated information

- Aggregated volume

- Price

- Aggregated total





Date of the transaction

15 March 2019


Place of the transaction

Off market


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit

a d v e r t i s e m e n t